Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

337.43
-12.5400-3.58%
Volume:116.90K
Turnover:39.62M
Market Cap:9.40B
PE:-25.28
High:349.44
Open:349.44
Low:332.18
Close:349.97
52wk High:366.52
52wk Low:37.19
Shares:27.85M
Float Shares:25.78M
Volume Ratio:0.53
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.3488
EPS(LYR):-13.4758
ROE:-35.32%
ROA:-23.04%
PB:6.67
PE(LYR):-25.04

Loading ...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX)

TIPRANKS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Eli Lilly & Co (LLY)

TIPRANKS
·
May 26

Praxis Precision Med Price Target Maintained With a $1245.00/Share by HC Wainwright & Co.

Dow Jones
·
May 26

Praxis Precision Med Price Target Maintained With a $843.00/Share by BTIG

Dow Jones
·
May 20

Praxis Highlights FDA NDA Acceptances and Strengthened Cash Runway

TIPRANKS
·
May 14

Praxis Precision Med Is Maintained at Buy by Truist Securities

Dow Jones
·
May 13

Praxis Precision Medicines Inc : Truist Securities Raises Target Price to $715 From $700

THOMSON REUTERS
·
May 13

Praxis Precision Medicines Maps High-Stakes Launch Path

TIPRANKS
·
May 12

Praxis Precision price target raised to $166 from $130 at Wedbush

TIPRANKS
·
May 08

Wedbush Remains a Sell on Praxis Precision Medicines (PRAX)

TIPRANKS
·
May 08

Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $420 From $444, Maintains Buy Rating

MT Newswires Live
·
May 08

Praxis Precision Medicines Inc : Wedbush Raises Target Price to $166 From $130

THOMSON REUTERS
·
May 08

Praxis Precision Medicines, Inc. : Deutsche Bank Cuts Target Price to $420 From $444

THOMSON REUTERS
·
May 08

H.C. Wainwright Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

TIPRANKS
·
May 08

Praxis Precision Med Price Target Maintained With a $843.00/Share by BTIG

Dow Jones
·
May 08

Praxis Therapeutics: Advancing Late-Stage Neurology Pipeline and De-Risked Ulixacaltamide NDA Support Unchanged $554 Buy Target

TIPRANKS
·
May 08

Praxis Precision Medicines publishes corporate presentation on CNS pipeline, near-term regulatory catalysts

Reuters
·
May 07

Praxis Precision's Q1 net loss widens on higher expenses

Reuters
·
May 07

Praxis Precision Medicine Q1 EPS $(3.20) Beats $(3.50) Estimate

Benzinga
·
May 07

BRIEF-Praxis Precision Q1 EPS USD -3.2

Reuters
·
May 07